Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : APMP (formerly APM) -- Ignore unavailable to you. Want to Upgrade?

To: WTMHouston who wrote (9435)	12/22/1997 1:20:00 AM
From: Follies	Respond to of 13456

**** 1 STOCK 1 week SECX Long Open 12/22 greatly oversold and undervalued

To: WTMHouston who wrote (9435)	12/22/1997 7:28:00 AM
From: tom pope	Respond to of 13456

*ONE STOCK - ONE WEEK* RXSD, LONG, 12/22 OPEN Favorable market reaction to earnings announcement may carry over this week. A negative is that I own it.

To: WTMHouston who wrote (9435)	12/22/1997 7:39:00 AM
From: Zakrosian	Read Replies (1) \| Respond to of 13456

*1 STOCK 1 WEEK* IOM open 12/22 Same basic reasons as last week, though with the added benefit of a late Friday conference call that apparently helped boost the share price late in the day. An uncertainty is how the split this week will affect the price movement - my guess is that IOM at 13 will look pretty appealing to small investors whose decisions could be more influential during a week of very low volume.

To: WTMHouston who wrote (9435)	12/22/1997 8:41:00 AM
From: Christopher Loe	Respond to of 13456

*ONE STOCK ONE WEEK* EVI - long at the open 12/22. Same reasons as last week even though it did not work out. I think stocks will actually do well this week, interests rates are still low and going lower, inflation still in check, a little Xmas rally on hand. I can't remember the market sinking into a bear when interests rates are falling and inflation is non-existant. Sure we have the Asian problem hanging over the market, but the fears will subside. Certainly risky to be long now because of market sentiment, but I'm not buying puts! Good luck to all. See ya! Merry Christmas to all!

To: WTMHouston who wrote (9435)	12/22/1997 9:16:00 AM
From: john p. carney	Respond to of 13456

*1 STOCK 1 WEEK* MCHM long Dec 22 open I'll try this again this week, for the same reasons as last week....I just hope the results are a little better. John

To: WTMHouston who wrote (9435)	12/22/1997 7:44:00 PM
From: AlienTech	Read Replies (1) \| Respond to of 13456

Oh man a lot of rusty traders out there.. Look at this WD-40 Co. (WDFC) 27 7/16 unch: manufacturer and marketer of multi-purpose lubricants posts a fiscal 1Q net of $0.34 a share, two cents better than the First Call estimate, vs year-ago net of $0.28 a share..... </b< squeek squeek... But i think merek is a STRONG BUY after the last 2 months.. MERCK & CO. INC. (MRK) 105 5/8 +3. This drug maker is getting a big push from investors today after the FDA approved Propecia, its drug that stops hair loss and encourages hair growth. While the drug does have some side-effects in around 2% of the patients that participated in the study, men are willing to try just about anything, even if it means lowering a person's sexual drive, in order to halt and reverse the trend in hair loss. The one-a-day pill is expected to cost between $45 and $49 for a monthly prescription supply and will be available to men only as studies have shown Propecia to cause birth defects in women. Propecia is expected to go head-to-head against Rogaine (PNU 36 5/8 +5/8), which is the only other FDA approved treatment available to fight hair loss. Given that there are an estimated 3 million users of Rogaine at the moment, if Merck is able to get about half this market to switch to its product, at $45 per month, the company could be generating as much as $810 million in additional revenues from Propecia. Of course, PNU will not stand still, and the added marketing costs will eat into the profits, but it seems that Merck could have a nice winner in this drug, even though the drug is not known to prevent hair loss from men who lose hair from the temples. Merck is on track to generate revenues of more than $23.7 billion in the current fiscal year from its global operations. Thus the 3% or more in additional revenues from this new drug could be significant if only the company can manage to have a good portion fall to the bottom line.